XPO1 and osteosarcoma: Overexpression of CRM1 is found in HNC [25,32], prostate cancer [13], breast cancer [14], cervical cancer [15], glioma [16], osteosarcoma [17], ovarian cancer [18], esophageal cancer [35], Kaposi’s sarcoma [36], pancreatic cancer [37], lung cancer [38], gastric cancer [39], renal cell carcinoma [39], hepatocellular carcinoma [41], acute myeloid/lymphoid leukemia [42], and chronic lymphoid leukemia [43], and this level of increase has been reported to be associated with metastasis, histological grade, increased tumor size, and lower overall survival.